125 related articles for article (PubMed ID: 8982031)
1. Extended multidrug resistance in haemopoietic cells.
Marks DC; Su GM; Davey RA; Davey MW
Br J Haematol; 1996 Dec; 95(4):587-95. PubMed ID: 8982031
[TBL] [Abstract][Full Text] [Related]
2. Development of extended multidrug resistance in HL60 promyelocytic leukaemia cells.
Su GM; Davey MW; Davey RA; Kidman AD
Br J Haematol; 1994 Nov; 88(3):566-74. PubMed ID: 7819069
[TBL] [Abstract][Full Text] [Related]
3. Induction of broad drug resistance in small cell lung cancer cells and its reversal by paclitaxel.
Su GM; Davey MW; Davey RA
Int J Cancer; 1998 May; 76(5):702-8. PubMed ID: 9610729
[TBL] [Abstract][Full Text] [Related]
4. Multidrug resistance in androgen-independent growing rat prostate carcinoma cells is mediated by P-glycoprotein.
Siegsmund MJ; Kreukler C; Steidler A; Nebe T; Köhrmann KU; Alken P
Urol Res; 1997; 25(1):35-41. PubMed ID: 9079744
[TBL] [Abstract][Full Text] [Related]
5. Drug resistance mechanisms and MRP expression in response to epirubicin treatment in a human leukaemia cell line.
Davey RA; Longhurst TJ; Davey MW; Belov L; Harvie RM; Hancox D; Wheeler H
Leuk Res; 1995 Apr; 19(4):275-82. PubMed ID: 7752673
[TBL] [Abstract][Full Text] [Related]
6. Differentiation and multidrug resistance in response to drug treatment in the K562 human leukaemia cell line.
Marks DC; Davey MW; Davey RA; Kidman AD
Br J Haematol; 1993 May; 84(1):83-9. PubMed ID: 8101722
[TBL] [Abstract][Full Text] [Related]
7. Differential expression and activity of P-glycoprotein and multidrug resistance-associated protein in CD34-positive KG1a leukemic cells.
Fardel O; Payen L; Courtois A; Drenou B; Fauchet R; Rault B
Int J Oncol; 1998 Feb; 12(2):315-9. PubMed ID: 9458355
[TBL] [Abstract][Full Text] [Related]
8. Development of drug resistance is reduced with idarubicin relative to other anthracyclines.
Hargrave RM; Davey MW; Davey RA; Kidman AD
Anticancer Drugs; 1995 Jun; 6(3):432-7. PubMed ID: 7670142
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein mediated resistance to 5'-nor-anhydro-vinblastine (Navelbine).
Adams DJ; Knick VC
Invest New Drugs; 1995; 13(1):13-21. PubMed ID: 7499103
[TBL] [Abstract][Full Text] [Related]
10. The expression of mdr-1-related gp-170 and its correlation with anthracycline resistance in renal cell carcinoma cell lines and multidrug-resistant sublines.
Yu DS; Chang SY; Ma CP
Br J Urol; 1998 Oct; 82(4):544-7. PubMed ID: 9806185
[TBL] [Abstract][Full Text] [Related]
11. Characterization and modulation of transitional cell carcinoma cell lines with acquired multidrug resistance.
Yu DS; Chang SY; Ma CP
Br J Urol; 1998 Feb; 81(2):234-40. PubMed ID: 9488065
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
[TBL] [Abstract][Full Text] [Related]
13. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
[TBL] [Abstract][Full Text] [Related]
15. Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative.
Dale IL; Tuffley W; Callaghan R; Holmes JA; Martin K; Luscombe M; Mistry P; Ryder H; Stewart AJ; Charlton P; Twentyman PR; Bevan P
Br J Cancer; 1998 Oct; 78(7):885-92. PubMed ID: 9764579
[TBL] [Abstract][Full Text] [Related]
16. The detection of rhodamine 123 efflux at low levels of drug resistance.
Webb M; Raphael CL; Asbahr H; Erber WN; Meyer BF
Br J Haematol; 1996 Jun; 93(3):650-5. PubMed ID: 8652387
[TBL] [Abstract][Full Text] [Related]
17. 17 beta-estradiol glucuronide: an inducer of cholestasis and a physiological substrate for the multidrug resistance transporter.
Gosland M; Tsuboi C; Hoffman T; Goodin S; Vore M
Cancer Res; 1993 Nov; 53(22):5382-5. PubMed ID: 8106146
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of multidrug-resistant Ehrlich ascites tumour cells selected in vivo for resistance to etoposide.
Nielsen D; Maare C; Eriksen J; Litman T; Friche E; Skovsgaard T
Biochem Pharmacol; 2000 Aug; 60(3):353-61. PubMed ID: 10856430
[TBL] [Abstract][Full Text] [Related]
19. Non-P-glycoprotein-mediated atypical multidrug resistance in a human bladder cancer cell line.
Naito S; Hasegawa S; Yokomizo A; Koga H; Kotoh S; Kuwano M; Kumazawa J
Jpn J Cancer Res; 1995 Nov; 86(11):1112-8. PubMed ID: 8567404
[TBL] [Abstract][Full Text] [Related]
20. Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients.
Ross DD; Doyle LA; Schiffer CA; Lee EJ; Grant CE; Cole SP; Deeley RG; Yang W; Tong Y
Leukemia; 1996 Jan; 10(1):48-55. PubMed ID: 8558937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
